Wall Street analysts predict that Opko Health Inc. (NASDAQ:OPK) will report sales of $262.52 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Opko Health’s earnings. The highest sales estimate is $268.10 million and the lowest is $259.67 million. Opko Health reported sales of $263.50 million during the same quarter last year, which indicates a negative year-over-year growth rate of 0.4%. The firm is scheduled to issue its next earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Opko Health will report full year sales of $1.04 billion for the current year, with estimates ranging from $1.03 billion to $1.05 billion. For the next year, analysts anticipate that the company will report sales of $1.07 billion, with estimates ranging from $1.03 billion to $1.09 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research analysts that follow Opko Health.

Opko Health (NASDAQ:OPK) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.06. Opko Health had a negative return on equity of 9.32% and a negative net margin of 31.73%. The firm had revenue of $263.69 million for the quarter, compared to analysts’ expectations of $260.37 million.

Several equities research analysts have weighed in on OPK shares. BidaskClub lowered Opko Health from a “strong-buy” rating to a “buy” rating in a research report on Thursday, August 16th. Cantor Fitzgerald reaffirmed a “buy” rating and issued a $20.00 target price on shares of Opko Health in a research report on Tuesday, August 7th. Barrington Research reaffirmed a “buy” rating and issued a $7.00 target price on shares of Opko Health in a research report on Friday, October 5th. Finally, ValuEngine raised Opko Health from a “sell” rating to a “hold” rating in a research report on Friday, September 7th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. Opko Health currently has a consensus rating of “Hold” and an average price target of $9.69.

OPK traded down $0.08 during trading hours on Friday, hitting $3.59. 3,255,600 shares of the stock were exchanged, compared to its average volume of 5,552,234. Opko Health has a 12 month low of $2.66 and a 12 month high of $6.99. The stock has a market capitalization of $2.13 billion, a PE ratio of -13.10 and a beta of 2.18. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.05 and a quick ratio of 0.90.

In related news, CEO Phillip Md Et Al Frost bought 55,000 shares of the company’s stock in a transaction on Tuesday, July 24th. The shares were purchased at an average cost of $5.60 per share, with a total value of $308,000.00. Following the completion of the transaction, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at $17,186,125.60. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders acquired 225,000 shares of company stock worth $1,210,850 over the last ninety days. 42.74% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently modified their holdings of the company. ING Groep NV acquired a new position in shares of Opko Health during the second quarter valued at $1,575,000. BlackRock Inc. grew its holdings in Opko Health by 38.7% during the second quarter. BlackRock Inc. now owns 29,531,554 shares of the biotechnology company’s stock worth $138,798,000 after acquiring an additional 8,237,434 shares during the period. Metropolitan Life Insurance Co. NY grew its holdings in Opko Health by 842.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 106,050 shares of the biotechnology company’s stock worth $498,000 after acquiring an additional 94,799 shares during the period. Rhumbline Advisers grew its holdings in Opko Health by 6.1% during the second quarter. Rhumbline Advisers now owns 337,168 shares of the biotechnology company’s stock worth $1,585,000 after acquiring an additional 19,316 shares during the period. Finally, Northern Trust Corp grew its holdings in Opko Health by 4.0% during the first quarter. Northern Trust Corp now owns 1,750,676 shares of the biotechnology company’s stock worth $5,549,000 after acquiring an additional 66,562 shares during the period. 24.70% of the stock is currently owned by institutional investors.

About Opko Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates Bio-Reference Laboratories, a clinical laboratory that offers laboratory testing services in the detection, diagnosis, evaluation, monitoring, and treatment of diseases.

Read More: Why do earnings reports matter?

Get a free copy of the Zacks research report on Opko Health (OPK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.